

出國報告（出國類別：開會）

2022 新加坡 ESMO Asia Congress 海報發表

服務機關：高雄榮民總醫院/病理檢驗部

姓名職稱：莊豪文/主治醫師

派赴國家：新加坡

出國期間：2022/12/02-2022/12/04

報告日期：2023/01/04

摘要

European Society for Medical Oncology (ESMO)成立於 1975 年，植根歐洲，業務遍及全球。ESMO 將具有不同專業知識和經驗的專業人士聯繫在一起，每年 ESMO 在世界各地，不同時間，會舉辦不同主題的腫瘤學國際討論會。2022 年 12 月 2-4 日在新加坡舉辦 ESMO Asia Congress 2022。有幸我的研究成果可以在該會議獲得展示海報的機會，得以參與此一盛會。當日有各類包括泌尿道腫瘤和頭頸部腫瘤的主題演講，雖然病理醫師的臨床業務是疾病診斷，了解臨床治療上的新的發展，更能和臨床醫師有更好的互動。這次海報展示是研究的初步成果，和與會學者的互動也獲得不少研究啟發，對於之後文章發表有很大助益，同時也看到各類主題的研究，增加拓展研究的思維和方法。

關鍵字

ESMO、腫瘤學

目次

一、目的.....	4
二、過程.....	4
三、心得及建議.....	5
附錄.....	5

一、目的

發表研究成果，吸取 oncology 新知，結識外國學者。

二、過程

European Society for Medical Oncology (ESMO)成立於 1975 年，植根歐洲，業務遍及全球。ESMO 將具有不同專業知識和經驗的專業人士聯繫在一起。它的教育和信息資源支持綜合的醫學腫瘤學多專業癌症治療方法。ESMO 是醫學腫瘤學的領先專業組織。ESMO 擁有來自全球 160 多個國家/地區的 28,000 多名成員，代表腫瘤學專業人士，是腫瘤學教育和信息的參考協會。每年 ESMO 在世界各地，不同時間，會舉辦不同主題的腫瘤學國際討論會。2022 年 12 月 2-4 日在新加坡舉辦 ESMO Asia Congress 2022。有幸我的研究成果可以在該會議獲得展示海報的機會，得以參與此一盛會。

我報名的是 12 月 3 日的議程，當日有泌尿道腫瘤和頭頸部腫瘤的主題。佈置完我的海報，我隨即先去會場聽 Front-line combination treatments in GU malignancies: How do we decide?的演講。會議中討論了 prostate cancer, urothelial cancer, 和 renal cell carcinoma 的治療進展。下午有 Potential benefits and limitations of IO in localised head and neck cancer 的演講，immunotherapy 在頭頸癌已有廣泛的應用。雖然病理醫師的臨床業務是疾病診斷，了解臨床治療上的新的發展，更能和臨床醫師有更好的互動。。

這次海報展示是研究的初步成果，與會學者也給了不少建議，對於之後文章發表有很大助益。會中也看到各國學者在不同領域的研究，有不少學者是發表案例報告，和臨床病例診裡的臨床病理分析報告。所以 ESMO 也是會接受這類型海報，對於剛起步的研究學者，有機會可以讓自己的成果在國際會議上被人看見。會中認識不少學者，也和生技廠商有所認識互動，晚上也受邀參加 AmoyDx 的學術演講，知道他們 Multiplex Polymerase Chain Reaction(Multiplex PCR)的產品。國內已有知名醫學中心在使用，未來本部可以考慮引進該產品，增進臨床服務品質。

總結，這次進行海報展示和討論，和與會學者的互動也獲得不少研究啟發，同時也看到各類主題的研究，增加拓展研究的思維和方法。整個會議收穫豐富，增進了不少知識，也認識了

不少外國學者。

三、心得及建議

Multiplex PCR 是可以考慮引進的技術。

附錄

ESMO Asia Congress 2022 - Conference Calen... Everything Search For x Q Advanced Search

Calendar view All Sessions All Presentations All e-Posters On-Demand Industry Satellite Symposia

Sessions are scheduled in Singapore Time (SGT)

Browsing Over 83 Sessions List Calendar

Fri, 02.12.2022 Sat, 03.12.2022 Sun, 04.12.2022

	Hall 406	Hall 405	Hall 404	Hall 4
08:00	New systemic treatment options for HCC: How to choose and... 08:00 - 08:45	State of the art and ongoing research in front line systemic... 08:00 - 08:45	Management of toxicities: New approaches 08:00 - 08:45	From pre- to rehabili Evidence till now an 08:00 - 08:45
09:00	Mini Oral session: Thoracic cancers 09:00 - 10:30	Front-line combination treatments in GU malignancies: How do we... 09:00 - 10:30	Mini Oral session: Breast cancer 09:00 - 10:30	Management of hae neoplasia in the era 09:00 - 09:45
10:00	Presidential Symposium 10:45 - 12:15			

Legend

- Educational session (8)
- Challenge your Expert (7)
- Special session (1)
- Proffered paper session (3)
- Mini oral session (5)
- Young oncologists (YO) session (2)
- Industry satellite symposium (5)

		Fri, 02.12.2022	Sat, 03.12.2022	Sun, 04.12.2022		
< Legend <ul style="list-style-type: none"> ■ Educational session (8) ■ Challenge your Expert (7) ■ Special session (1) ■ Proffered paper session (3) ■ Mini oral session (5) ■ Young oncologists (YO) session (2) ■ Industry satellite symposium (5) 	09:00	Hall 406	Hall 405	Hall 404	Hall 4	
	10:00					
	11:00		Presidential Symposium 10:45 - 12:15			
	12:00					
	13:00			12:45 - 14:15 AstraZeneca - Navigating the complexity in NSCLC: Optimising the patient journey	12:45 - 14:15 Astellas Pharma - The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin	INVITATION Merck KGaA, Darmstadt - Pfizer Alliance treatment outcome urothelial carcinoma metastatic renal cell carcinoma View the full invitation
	14:00		Cancer immunotherapy in 2022 14:30 - 16:00	Potential benefits and limitations of IO in localised head and neck... 14:30 - 16:00	Proffered Paper and Mini Oral session: Gastrointestinal tumours 14:30 - 15:30	Mini Oral session: Gastrointestinal tumours 14:30 - 16:00

		Fri, 02.12.2022	Sat, 03.12.2022	Sun, 04.12.2022	
< Legend <ul style="list-style-type: none"> ■ Educational session (8) ■ Challenge your Expert (7) ■ Special session (1) ■ Proffered paper session (3) ■ Mini oral session (5) ■ Young oncologists (YO) session (2) ■ Industry satellite symposium (5) 	14:00	Cancer immunotherapy in 2022 14:30 - 16:00	Potential benefits and limitations of IO in localised head and neck... 14:30 - 16:00	Proffered Paper and Mini Oral session: Gastrointestinal tumours 14:30 - 15:30	Mini Oral session: Gastrointestinal tumours 14:30 - 16:00
	15:00				
	16:00	Lung cancer in non-smokers 16:15 - 17:45	Proffered Paper session: Genitourinary tumours 16:15 - 17:00	Immunotherapy in gynecological cancers: Where do we stand? 16:15 - 17:45	Mini Oral session: Supportive and palliative care 16:15 - 17:45
	17:00				
	18:00				



Front-line combination treatments in GU malignancies: How do we decide?的演講



Certificate of attendance

for

ESMO Asia Congress 2022

Hao-Wen Chuang
Taiwan

The Congress programme has been accredited for a maximum of
25 ESMO-MORA category 1 points.

The ESMO Medical Oncologist's Recertification Approval (MORA) is a continuing medical education certificate that allows ESMO members to remain certified in medical oncology.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology.



海報展場

240P SERPINE2 Promotes the Growth, Invasion, and Metastasis in Oral Squamous Cell Carcinoma and is Associated with Poor Prognosis

Hao-Wan Chuang^{1,2}, Li-Han Lin³, Heng-Sheng Lee¹, Shing-Cheng Tseng¹, Ken-Tai Hsieh³
¹Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.
²Institute of Oral Biology, School of Dentistry, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
³Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan, ROC.

BACKGROUND: To investigate the role of the *serpin peptidase inhibitor, clade E, member 2 (SERPINE2)*, in patients with oral squamous cell carcinoma (OSCC).

METHODS: We investigated SERPINE2 mRNA expression in cases of squamous cell carcinoma from online databases, explored the relationship between SERPINE2 and clinicopathological characteristics and prognosis in OSCC patients, and determined the potential of SERPINE2 to affect OSCC proliferation, migration and invasion capability in vitro.

RESULTS:

The expressions of SERPINE2 were higher in tumor tissues than that in normal tissues in TMPlot. High mRNA expression of SERPINE2 was significantly correlated with poor overall 5-year survival in KIPLOT.

Parameters	No.	Mean ± SEM	Median	P
Age^a				
≤ 54	73	147.47 ± 7.71	100	0.132
> 54	49	163.85 ± 8.86	165	
Gender^a				
Male	107	152.59 ± 6.43	100	0.361
Female	15	164.33 ± 13.31	180	
Tumor site^a				
Buccal	77	152.09 ± 7.20	100	0.700
Alveolar	24	148.95 ± 13.50	165	
Hard ^b	7	170.34 ± 25.33	170	
Others	14	165.36 ± 19.25	171	
Histological grade^a				
Well	45	149.00 ± 8.18	105	0.720
Moderate	71	156.15 ± 8.33	160	
Poor	6	167.06 ± 30.81	183	
Stage^a				
I-II	66	133.60 ± 7.41	113	<0.001*
III-IV	56	178.12 ± 8.34	184	
Tumor status^a				
T1-2	78	139.20 ± 7.18	100	<0.001*
T3-4	44	190.34 ± 8.94	194	
Stromal metastasis^a				
Absent	91	143.36 ± 6.30	100	0.003*
Present	31	179.52 ± 12.64	180	
Distant metastasis^a				
Absent	107	148.69 ± 6.36	100	0.008*
Present	15	192.17 ± 11.12	188	

^ap-value by Mann-Whitney U test; ^bp-value by Kruskal-Wallis test
*Significant at p < 0.05.

SERPINE2 promotes cell proliferation, cell migration, and invasion ability in OSCC cell lines.


CONCLUSIONS: SERPINE2 may serve as a prognostic biomarker, associated with the tumorigenesis and aggressiveness of OSCC.

DISCLOSURES: The authors declare that they have no conflict of interest.

Contact: hwc_alb@hotmail.com
 Study sponsored by a grant from Kaohsiung Veterans General Hospital (grant number VGHKS108-074) in Taiwan, ROC.



會場留影



海報合影